1-4 of 4
C O'Brien
Close
Sort by
Journal Articles

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Mark B. Geyer, MD, Amber C. King, PharmD, BCOP, Justin C. O'Brien, Jae H. Park, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45.
https://doi.org/10.1182/blood-2020-137016
Published: 2020
Journal Articles

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, PhD, Amanda C. O’Brien, Brooke Hayward, SM, Steven Arkin, MD, David A. Roth, MD
Journal: Blood
Blood (2008) 112 (11): 1229.
https://doi.org/10.1182/blood.V112.11.1229.1229
Published: 2008
Journal Articles

ReFacto AF Is Effective and Safe in Previously Treated Patients with Severe Hemophilia A: Final Results of a Pivotal Phase III Study.

Michael Recht, MD, PhD, Laszlo Nemes, MD, Amanda C. O’Brien, Chandrasekhar Udata, PhD, David Roth, MD, Steven Arkin, MD
Journal: Blood
Blood (2007) 110 (11): 1151.
https://doi.org/10.1182/blood.V110.11.1151.1151
Published: 2007
Journal Articles

Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia

SE Sallan, J Ritz, J Pesando, R Gelber, C O'Brien, S Hitchcock, F Coral, SF Schlossman
Journal: Blood
Blood (1980) 55 (3): 395–402.
https://doi.org/10.1182/blood.V55.3.395.395
Published: 1980